Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a ...

Altoida’s AI-powered device to indicate Alzheimer’s in adults with mild cognitive dementia was given breakthrough designation by the FDA.

Based on new data from an ongoing trial, Eisai and Biogen's lecanemab for early Alzheimer’s was granted FDA breakthrough therapy status.

Holidays can be difficult for caregivers who have a loved one with dementia, writes columnist Ray Burow. But celebrating is still possible.

A dual vaccine targeting both amyloid plaques and tangled fibers made up of tau may have potential to treat and prevent Alzheimer’s disease.

Intranasal, or into-the-nose, delivery of foralumab, an investigational antibody-based treatment being developed by Tiziana Life Sciences, restored the activity of microglial cells and improved ...

After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.

Potential stroke therapy 3K3A-APC, about to enter a Phase 3 trial, may also help protect the brain against Alzheimer's and other dementias.

While there is no cure for Alzheimer’s disease, nor have any disease-modifying therapies been approved yet, there are several medications available by prescription to treat disease symptoms that ...

In a significant decision, the FDA approved Adulhelm (aducanumab) as a first targeted Alzheimer's treatment, and first new therapy since 2003.

Moderate alcohol intake in middle-aged and older people who don't show signs of dementia is associated with lower deposits of amyloid-beta, a study found.